DNB Markets - Episurf Medical: CMD and Q3 results
Episurf Medical hosted a CMD on 16 November at which it discussed the state of the company and its long-term plans. International expansion will be even more important in the future, in our view. The company is still suffering from the effects of the pandemic, and Q3 sales were thus lower than we expected, though its operating losses were in line with our forecast. We reiterate our fair value for Episurf of SEK3.3–9.3.CMD summary. Episurf Medical hosted a CMD on 16 November, which focused on its plans and product portfolio and talks by Key Opinion Leaders on the data and results for the